

CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

[1]

Ahmed, R.M. et al. 2016. Neuronal network disintegration: common pathways linking neurodegenerative diseases. *Journal of Neurology, Neurosurgery & Psychiatry*. 87, 11 (Nov. 2016), 1234–1241. DOI:<https://doi.org/10.1136/jnnp-2014-308350>.

[2]

Alzheimer's Facts and Figures Report | Alzheimer's Association:
<https://www.alz.org/alzheimers-dementia/facts-figures>.

[3]

Arash Asher The effect of cancer treatment on cognitive function. undefined.

[4]

Barker, R.A. and Williams-Gray, C.H. 2016. Review: The spectrum of clinical features seen with alpha synuclein pathology. *Neuropathology and Applied Neurobiology*. 42, 1 (Feb. 2016), 6–19. DOI:<https://doi.org/10.1111/nan.12303>.

[5]

Bates, G.P. et al. 2015. Huntington disease. *Nature Reviews Disease Primers*. (Apr. 2015). DOI:<https://doi.org/10.1038/nrdp.2015.5>.

[6]

Blennow, K. et al. 2012. The Neuropathology and Neurobiology of Traumatic Brain Injury. *Neuron*. 76, 5 (Dec. 2012), 886–899. DOI:<https://doi.org/10.1016/j.neuron.2012.11.021>.

[7]

Braak, H. and Braak, E. 1995. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging*. 16, 3 (May 1995), 271–278. DOI:[https://doi.org/10.1016/0197-4580\(95\)00021-6](https://doi.org/10.1016/0197-4580(95)00021-6).

[8]

Bras, J. et al. 2014. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*. 23, 23 (Dec. 2014), 6139–6146. DOI:<https://doi.org/10.1093/hmg/ddu334>.

[9]

Carroll, J.B. et al. 2015. Treating the whole body in Huntington's disease. *The Lancet Neurology*. 14, 11 (Nov. 2015), 1135–1142. DOI:[https://doi.org/10.1016/S1474-4422\(15\)00177-5](https://doi.org/10.1016/S1474-4422(15)00177-5).

[10]

Clarke, C. et al. eds. 2016. *Neurology: a Queen Square textbook*. Wiley Blackwell.

[11]

Collinge, J. 2016. Mammalian prions and their wider relevance in neurodegenerative diseases. *Nature*. 539, 7628 (Nov. 2016), 217–226. DOI:<https://doi.org/10.1038/nature20415>.

[12]

De Chiara, G. et al. 2012. Infectious Agents and Neurodegeneration. *Molecular Neurobiology*. 46, 3 (Dec. 2012), 614–638. DOI:<https://doi.org/10.1007/s12035-012-8320-7>.

[13]

Devenney, E. et al. 2015. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics*. 15, 5 (May 2015), 509–522.
DOI:<https://doi.org/10.1586/14737175.2015.1034108>.

[14]

Dobson, R. and Alvares, D. 2016. The difficulties with vitamin B. *Practical Neurology*. 16, 4 (Aug. 2016), 308–311. DOI:<https://doi.org/10.1136/practneurol-2015-001344>.

[15]

Dubois, B. et al. 2014. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *The Lancet Neurology*. 13, 6 (Jun. 2014), 614–629.
DOI:[https://doi.org/10.1016/S1474-4422\(14\)70090-0](https://doi.org/10.1016/S1474-4422(14)70090-0).

[16]

Fleminger, S. 2003. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *Journal of Neurology, Neurosurgery & Psychiatry*. 74, 7 (Jul. 2003), 857–862. DOI:<https://doi.org/10.1136/jnnp.74.7.857>.

[17]

Fletcher, P.D. and Warren, J.D. 2011. Semantic Dementia: a specific network-opathy. *Journal of Molecular Neuroscience*. 45, 3 (Nov. 2011), 629–636.
DOI:<https://doi.org/10.1007/s12031-011-9586-3>.

[18]

Ghanem, K.G. 2010. REVIEW: Neurosyphilis: A Historical Perspective and Review. *CNS Neuroscience & Therapeutics*. 16, 5 (Oct. 2010), e157–e168.
DOI:<https://doi.org/10.1111/j.1755-5949.2010.00183.x>.

[19]

Goll, J.C. et al. 2010. Central auditory disorders: toward a neuropsychology of auditory objects. *Current Opinion in Neurology*. 23, 6 (Dec. 2010), 617–627.
DOI:<https://doi.org/10.1097/WCO.0b013e32834027f6>.

[20]

Goll, J.C. et al. 2012. Nonverbal sound processing in semantic dementia: A functional MRI study. *NeuroImage*. 61, 1 (May 2012), 170–180.
DOI:<https://doi.org/10.1016/j.neuroimage.2012.02.045>.

[21]

Goll, J.C. et al. 2010. Non-verbal sound processing in the primary progressive aphasia. *Brain*. 133, 1 (Jan. 2010), 272–285. DOI:<https://doi.org/10.1093/brain/awp235>.

[22]

Gordon, E. et al. 2016. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry*. 138, (Aug. 2016), 193–210. DOI:<https://doi.org/10.1111/jnc.13656>.

[23]

Gorelick, P.B. et al. 2011. Vascular Contributions to Cognitive Impairment and Dementia. *Stroke*. 42, 9 (Sep. 2011), 2672–2713.
DOI:<https://doi.org/10.1161/STR.0b013e3182299496>.

[24]

Gorno-Tempini, M.L. et al. 2011. Classification of primary progressive aphasia and its variants. *Neurology*. 76, 11 (Mar. 2011), 1006–1014.
DOI:<https://doi.org/10.1212/WNL.0b013e31821103e6>.

[25]

Graus, F. et al. 2016. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. 15, 4 (Apr. 2016), 391–404.
DOI:[https://doi.org/10.1016/S1474-4422\(15\)00401-9](https://doi.org/10.1016/S1474-4422(15)00401-9).

[26]

Graus, F. et al. 2016. A clinical approach to diagnosis of autoimmune encephalitis. *The*

Lancet Neurology. 15, 4 (Apr. 2016), 391–404.
DOI:[https://doi.org/10.1016/S1474-4422\(15\)00401-9](https://doi.org/10.1016/S1474-4422(15)00401-9).

[27]

Green, A.J.E. 2018. RT-QuIC: a new test for sporadic CJD. Practical Neurology. (Oct. 2018).
DOI:<https://doi.org/10.1136/practneurol-2018-001935>.

[28]

Grossman, M. 2012. The non-fluent/agrammatic variant of primary progressive aphasia. The Lancet Neurology. 11, 6 (Jun. 2012), 545–555.
DOI:[https://doi.org/10.1016/S1474-4422\(12\)70099-6](https://doi.org/10.1016/S1474-4422(12)70099-6).

[29]

Hachinski, V. et al. 2006. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke. 37, 9 (Sep. 2006), 2220–2241. DOI:<https://doi.org/10.1161/01.STR.0000237236.88823.47>.

[30]

Haddow, L.J. et al. 2013. HIV and the brain: from AIDS to old age. Clinical Medicine. 13, Suppl_6 (Dec. 2013), s24–s28. DOI:<https://doi.org/10.7861/clinmedicine.13-6-s24>.

[31]

Halliday, G.M. et al. 2011. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica. 122, 2 (Aug. 2011), 187–204.
DOI:<https://doi.org/10.1007/s00401-011-0852-9>.

[32]

Halperin, J.J. et al. 2015. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. Neurology. 85, 23 (Dec. 2015), 2063–2071. DOI:<https://doi.org/10.1212/WNL.0000000000002193>.

[33]

Hardy, C.J.D. et al. 2016. Hearing and dementia. *Journal of Neurology*. 263, 11 (Nov. 2016), 2339–2354. DOI:<https://doi.org/10.1007/s00415-016-8208-y>.

[34]

Hereditary and sporadic beta-amyloidoses:
<https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>.

[35]

HIV in the United Kingdom 2016 infographic:
<https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>.

[36]

Hodges, J.R. 2017. *Cognitive assessment for clinicians*. Oxford University Press.

[37]

Hollak, C.E.M. and Lachmann, R. eds. 2016. *Inherited metabolic disease in adults: a clinical guide*. Oxford University Press.

[38]

Husain, M. 2016. *Oxford textbook of cognitive neurology and dementia*. Oxford University Press.

[39]

Husain, M. 2016. *Oxford textbook of cognitive neurology and dementia*. Oxford University Press.

[40]

Iranzo, A. et al. 2014. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior

Disorder: Study in 174 Patients. PLoS ONE. 9, 2 (Feb. 2014).
DOI:<https://doi.org/10.1371/journal.pone.0089741>.

[41]

Itzhaki, R.F. et al. 2016. Microbes and Alzheimer's Disease. Journal of Alzheimer's Disease. 51, 4 (Apr. 2016), 979–984. DOI:<https://doi.org/10.3233/JAD-160152>.

[42]

Johnson, G.V.W. 2004. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science. 117, 24 (Nov. 2004), 5721–5729.
DOI:<https://doi.org/10.1242/jcs.01558>.

[43]

Johnson, K.A. et al. 2012. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine. 2, 4 (Apr. 2012), a006213–a006213.
DOI:<https://doi.org/10.1101/cshperspect.a006213>.

[44]

Jonathan Carr 2003. Neurosyphilis. Practical Neurology. 3, (Dec. 2003), 328–341.

[45]

Jones, L. et al. 2017. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology. 16, 1 (Jan. 2017), 88–96. DOI:[https://doi.org/10.1016/S1474-4422\(16\)30350-7](https://doi.org/10.1016/S1474-4422(16)30350-7).

[46]

Kandel, E.R. et al. eds. 2013. Principles of neural science. McGraw Hill Medical.

[47]

Karran, E. and Hardy, J. 2014. Anti-amyloid Therapy for Alzheimer's Disease — Are We on

the Right Road? *New England Journal of Medicine*. 370, 4 (Jan. 2014), 377–378.
DOI:<https://doi.org/10.1056/NEJMe1313943>.

[48]

Kielb, S.A. et al. 2012. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. *NeuroMolecular Medicine*. 14, 3 (Sep. 2012), 180–193. DOI:<https://doi.org/10.1007/s12017-012-8182-1>.

[49]

Leys, D. et al. 2005. Poststroke dementia. *The Lancet Neurology*. 4, 11 (Nov. 2005), 752–759. DOI:[https://doi.org/10.1016/S1474-4422\(05\)70221-0](https://doi.org/10.1016/S1474-4422(05)70221-0).

[50]

Leyton, C.E. et al. 2015. Is the logopenic-variant of primary progressive aphasia a unitary disorder? *Cortex*. 67, (Jun. 2015), 122–133.
DOI:<https://doi.org/10.1016/j.cortex.2015.03.011>.

[51]

Livingston, G. et al. 2017. Dementia prevention, intervention, and care. *The Lancet*. 390, 10113 (Dec. 2017), 2673–2734. DOI:[https://doi.org/10.1016/S0140-6736\(17\)31363-6](https://doi.org/10.1016/S0140-6736(17)31363-6).

[52]

Loy, C.T. et al. 2014. Genetics of dementia. *The Lancet*. 383, 9919 (Mar. 2014), 828–840.
DOI:[https://doi.org/10.1016/S0140-6736\(13\)60630-3](https://doi.org/10.1016/S0140-6736(13)60630-3).

[53]

Lynch, D.S. et al. 2017. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain*. 140, 5 (May 2017), 1204–1211. DOI:<https://doi.org/10.1093/brain/awx045>.

[54]

Mander, B.A. et al. 2016. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? *Trends in Neurosciences*. 39, 8 (Aug. 2016), 552–566. DOI:<https://doi.org/10.1016/j.tins.2016.05.002>.

[55]

Marshall, C.R. et al. 2018. Primary progressive aphasia: a clinical approach. *Journal of Neurology*. 265, 6 (Jun. 2018), 1474–1490. DOI:<https://doi.org/10.1007/s00415-018-8762-6>.

[56]

McCarter, S.J. et al. 2016. Sleep Disturbances in Frontotemporal Dementia. *Current Neurology and Neuroscience Reports*. 16, 9 (Sep. 2016). DOI:<https://doi.org/10.1007/s11910-016-0680-3>.

[57]

McCarthy, R.A. and Warrington, E.K. 1990. *Cognitive neuropsychology: a clinical introduction*. Academic Press, Inc.

[58]

McKee, A.C. et al. 2013. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 136, 1 (Jan. 2013), 43–64. DOI:<https://doi.org/10.1093/brain/aws307>.

[59]

McKeith, I.G. et al. 2017. Diagnosis and management of dementia with Lewy bodies. *Neurology*. 89, 1 (Jul. 2017), 88–100. DOI:<https://doi.org/10.1212/WNL.0000000000004058>.

[60]

Mead, S. and Rudge, P. 2017. CJD mimics and chameleons. *Practical Neurology*. 17, 2 (Apr. 2017), 113–121. DOI:<https://doi.org/10.1136/practneurol-2016-001571>.

[61]

Mirra, S.S. et al. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 41, 4 (Apr. 1991), 479–479. DOI:<https://doi.org/10.1212/WNL.41.4.479>.

[62]

Montine, T.J. et al. 2012. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*. 123, 1 (Jan. 2012), 1–11. DOI:<https://doi.org/10.1007/s00401-011-0910-3>.

[63]

Montine, T.J. et al. 2012. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*. 123, 1 (Jan. 2012), 1–11. DOI:<https://doi.org/10.1007/s00401-011-0910-3>.

[64]

Nightingale, S. et al. 2014. Controversies in HIV-associated neurocognitive disorders. *The Lancet Neurology*. 13, 11 (Nov. 2014), 1139–1151. DOI:[https://doi.org/10.1016/S1474-4422\(14\)70137-1](https://doi.org/10.1016/S1474-4422(14)70137-1).

[65]

Nightingale, S. et al. 2013. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. *Practical Neurology*. 13, 6 (Dec. 2013), 354–356. DOI:<https://doi.org/10.1136/practneurol-2013-000689>.

[66]

O'Brien, J.T. and Thomas, A. 2015. Vascular dementia. *The Lancet*. 386, 10004 (Oct. 2015), 1698–1706. DOI:[https://doi.org/10.1016/S0140-6736\(15\)00463-8](https://doi.org/10.1016/S0140-6736(15)00463-8).

[67]

Ooms, S. and Ju, Y.-E. 2016. Treatment of Sleep Disorders in Dementia. *Current Treatment Options in Neurology*. 18, 9 (Sep. 2016). DOI:<https://doi.org/10.1007/s11940-016-0424-3>.

[68]

Revesz, T. et al. 2009. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica*. 118, 1 (Jul. 2009), 115–130. DOI:<https://doi.org/10.1007/s00401-009-0501-8>.

[69]

Richard W. Price and Bruce J. Brew 1988. The AIDS Dementia Complex. *The Journal of Infectious Diseases*. 158, 5 (1988).

[70]

Rohrer, J.D. et al. 2010. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage*. 49, 1 (Jan. 2010), 984–993. DOI:<https://doi.org/10.1016/j.neuroimage.2009.08.002>.

[71]

Rohrer, J.D. et al. 2012. Receptive prosody in nonfluent primary progressive aphasia. *Cortex*. 48, 3 (Mar. 2012), 308–316. DOI:<https://doi.org/10.1016/j.cortex.2010.09.004>.

[72]

Rohrer, J.D. et al. 2010. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology*. 75, 7 (Aug. 2010), 603–610. DOI:<https://doi.org/10.1212/WNL.0b013e3181ed9c6b>.

[73]

Rohrer, J.D. et al. 2007. Word-finding difficulty: a clinical analysis of the progressive aphasia. *Brain*. 131, 1 (Dec. 2007), 8–38. DOI:<https://doi.org/10.1093/brain/awm251>.

[74]

Ross, C.A. et al. 2014. Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nature Reviews Neurology*. 10, 4 (Apr. 2014), 204–216.
DOI:<https://doi.org/10.1038/nrneurol.2014.24>.

[75]

Rossor, M. et al. 2016. Dementia and Cognitive Impairment. *Neurology*. C. Clarke et al., eds. John Wiley & Sons, Ltd. 289–336.

[76]

Rossor, M. and Growdon, J.H. 2007. *The dementias 2*. Butterworth Heinemann/Elsevier.

[77]

Rossor, M.N. et al. 2010. The diagnosis of young-onset dementia. *The Lancet Neurology*. 9, 8 (Aug. 2010), 793–806. DOI:[https://doi.org/10.1016/S1474-4422\(10\)70159-9](https://doi.org/10.1016/S1474-4422(10)70159-9).

[78]

Salvarani, C. et al. 2012. Adult primary central nervous system vasculitis. *The Lancet*. 380, 9843 (Aug. 2012), 767–777. DOI:[https://doi.org/10.1016/S0140-6736\(12\)60069-5](https://doi.org/10.1016/S0140-6736(12)60069-5).

[79]

Schott, J.M. et al. 2016. Assessment and investigation of the cognitively impaired adult. *Oxford Textbook of Cognitive Neurology and Dementia*. M. Husain and J.M. Schott, eds. Oxford University Press. 221–230.

[80]

Scott, G. et al. 2016. Amyloid pathology and axonal injury after brain trauma. *Neurology*. 86, 9 (Mar. 2016), 821–828. DOI:<https://doi.org/10.1212/WNL.0000000000002413>.

[81]

Selkoe, D.J. and Hardy, J. 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*. 8, 6 (Jun. 2016), 595–608.
DOI:<https://doi.org/10.15252/emmm.201606210>.

[82]

Smith, D.H. et al. 2013. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? *Nature Reviews Neurology*. 9, 4 (Apr. 2013), 211–221.
DOI:<https://doi.org/10.1038/nrneurol.2013.29>.

[83]

Somasundaram, O. 2009. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. *Indian Journal of Psychiatry*. 51, 3 (2009). DOI:<https://doi.org/10.4103/0019-5545.55103>.

[84]

Strong, M.J. et al. 2017. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 18, 3–4 (Apr. 2017), 153–174.
DOI:<https://doi.org/10.1080/21678421.2016.1267768>.

[85]

Tabrizi, S.J. et al. 2011. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *The Lancet Neurology*. 10, 1 (Jan. 2011), 31–42.
DOI:[https://doi.org/10.1016/S1474-4422\(10\)70276-3](https://doi.org/10.1016/S1474-4422(10)70276-3).

[86]

Tabrizi, S.J. et al. 2012. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *The Lancet Neurology*. 11, 1 (Jan. 2012), 42–53.
DOI:[https://doi.org/10.1016/S1474-4422\(11\)70263-0](https://doi.org/10.1016/S1474-4422(11)70263-0).

[87]

Tabrizi, S.J. et al. 2013. Predictors of phenotypic progression and disease onset in

premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *The Lancet Neurology*. 12, 7 (Jul. 2013), 637–649. DOI:[https://doi.org/10.1016/S1474-4422\(13\)70088-7](https://doi.org/10.1016/S1474-4422(13)70088-7).

[88]

Thal, D.R. 2004. Neurodegeneration in Normal Brain Aging and Disease. *Science of Aging Knowledge Environment*. 2004, 23 (Jun. 2004), pe26–pe26. DOI:<https://doi.org/10.1126/sageke.2004.23.pe26>.

[89]

UK National Guidelines for HIV Testing 2008: <https://www.bhiva.org/HIV-testing-guidelines>.

[90]

Walker, Z. et al. 2015. Lewy body dementias. *The Lancet*. 386, 10004 (Oct. 2015), 1683–1697. DOI:[https://doi.org/10.1016/S0140-6736\(15\)00462-6](https://doi.org/10.1016/S0140-6736(15)00462-6).

[91]

Warren, J.D. et al. 2013. Frontotemporal dementia. *BMJ*. 347, aug12 3 (Aug. 2013), f4827–f4827. DOI:<https://doi.org/10.1136/bmj.f4827>.

[92]

Weil, R.S. et al. 2017. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. *F1000Research*. 6, (Aug. 2017). DOI:<https://doi.org/10.12688/f1000research.11725.1>.

[93]

Wendorf, K.A. et al. 2017. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. *Clinical Infectious Diseases*. 65, 2 (Jul. 2017), 226–232. DOI:<https://doi.org/10.1093/cid/cix302>.

[94]

Wild, E.J. and Tabrizi, S.J. 2017. Therapies targeting DNA and RNA in Huntington's disease. *The Lancet Neurology*. 16, 10 (Oct. 2017), 837–847.
DOI:[https://doi.org/10.1016/S1474-4422\(17\)30280-6](https://doi.org/10.1016/S1474-4422(17)30280-6).

[95]

Woollacott, I.O.C. and Rohrer, J.D. 2016. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry*. 138, (Aug. 2016), 6–31.
DOI:<https://doi.org/10.1111/jnc.13654>.

[96]

Zhou, L. et al. 2013. Viruses and neurodegeneration. *Virology Journal*. 10, 1 (2013).
DOI:<https://doi.org/10.1186/1743-422X-10-172>.

[97]

2018. Cognitive Impairment Associated with Cancer: A Brief Review. *Innovations in Clinical Neuroscience*. 15, 1–2 (2018).

[98]

2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *The Lancet*. 357, 9251 (Jan. 2001), 169–175.
DOI:[https://doi.org/10.1016/S0140-6736\(00\)03589-3](https://doi.org/10.1016/S0140-6736(00)03589-3).